Volume 8, Issue 4, July 2022

Focus on different aspects of atrial fibrillation

• Extract
• View article

Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis

• Abstract
• View article
• Supplementary data

Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients

• Abstract
• View article
• Supplementary data

Weekend vs. weekday admission and clinical outcomes in heart failure patients with and without atrial fibrillation in Taiwan

• Abstract
• View article

Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study

• Abstracts
• View article
• Supplementary data

Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial

• Abstracts
• View article
• Supplementary data

Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC–EHRA EORP AF Long-Term General Registry

• Abstract
• View article
• Supplementary data

Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events

• Abstracts
• View article

Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis

• Abstract
• View article
• Supplementary data

Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19

• Abstract
• View article

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

• Abstract
• View article
• Supplementary data

Photoinduced skin reactions of cardiovascular drugs—a systematic review

• Abstract
• View article